The rise of direct-to-consumer channels, driven largely by consumer willingness to pay for GLP-1s for weight loss without using insurance, is leading to new arrangements between pharmaceutical companies and employers that oversee healthcare coverage for their employees.
Pharmaceutical companies’ ability to interact with the patients taking their medications has changed over the last few years.
The rise of direct-to-consumer channels, driven largely …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
The Case for Direct-to-Patient Is Clear, The Challenge Now is Successful Execution
L’industrie pharmaceutique confrontée au risque de dépendance aux traitements contre l’obésité - Le Temps
Maintaining weight loss in obesity goes beyond GLP-1s: ‘The hard work is just beginning’
STEFAN SWANEPOEL | GLP-1 adoption may boost longevity, alter SA economy
